Tech Company Financing Transactions
Enlaza Therapeutics Funding Round
Enlaza Therapeutics, based in La Jolla, secured $100 million from JPMorgan Partners, Alexandria Venture Investments and Amgen Ventures.
Transaction Overview
Company Name
Announced On
4/30/2024
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to further develop its proprietary covalent protein technologies and advance wholly owned pipeline programs to the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11099 North Torrey Pines Rd 280
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Undisclosed
Website
Email Address
Overview
Enlaza is creating a groundbreaking new class of protein therapeutics that deliver more efficacious and safer treatments for patients. Enlaza's breakthrough War-LockTM technology enables generation of unique, highly-selective biologic drugs that are engineered to become warheads with the capacity to irreversibly lock to disease related targets. We leverage our novel synthetic biology platform, coupled with proprietary amino acids, to precision-engineer biological medicines with improved efficacy and safety profiles.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sergio Duron
Chief Scientific Officer
Analeah Heidt
Co-Founder
Sanford Madigan
Vice President
Sergio Duron
Vice President
Emily Rowell
Browse more venture capital transactions:
Prev: 4/30/2024: Urban Jungle venture capital transaction
Next: 4/30/2024: X10 venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs